Takeda Launches First Asian Innovation Capability Center in Bengaluru, Focusing on AI and Digital Health Solutions

Takeda's 1st Asian Innovation Center Comes Up in Bengaluru

Takeda, a global biopharmaceutical leader, inaugurated its innovation capability centre (ICC) in Bengaluru on Wednesday, marking its first such facility in Asia. The centre is part of Takeda's global digital transformation efforts to develop advanced solutions and enhance its operations worldwide. The ICC aims to harness digital technologies like AI to accelerate research and development and improve healthcare outcomes. "The launch of our Bengaluru ICC is a pivotal moment in Takeda's digital transformation journey," said chief data and technology officer Gabriele Ricci. "Tapping into local talent is vital in our quest to create better health for people and a brighter future for the communities we serve," he added. The Bengaluru ICC will focus on using AI to enhance healthcare efficiency and predictive analytics, developing innovative devices and solutions tailored to patient's needs. It will leverage data science to enable informed decision-making for improved patient care. The ICC in Bengaluru is Takeda's third such centre, complementing existing hubs in Mexico and Slovakia. It is designed to foster innovation, improve operational efficiency, and accelerate the development of life-transforming therapies. "The Bengaluru site is our flagship ICC, forming part of a network that is the digital heart of Takeda," said Sanjay Patel, global head of innovation capability solutions and services." This centre is expected to generate jobs in India and strengthen Takeda's global mission to deliver life-changing treatments to patients. "India was a natural choice for Takeda's first ICC in Asia," said Tilak Banerjee, head of Takeda ICC India. The ICC will employ 750 professionals by the end of the year with expertise in software engineering, data analysis, and AI. It will also play a pivotal role in supporting the company's broader global operations, including research and development, manufacturing, and plasma donor systems. The solutions developed here will benefit patients, healthcare providers, and employees worldwide. Founded in 1781 in Osaka, Japan, Takeda has grown into a global biopharmaceutical giant operating in about 80 countries, including India, for over 13 years. The company's portfolio covers areas such as gastrointestinal disorders, rare diseases, immunology, oncology, and vaccines.

Takeda Expands Presence in India with Launch of Global Innovation Capability Center in Bengaluru T

Takeda Innovation Capability Center to Fill Upwards of 750 Roles, Strengthening Bengaluru's Global Innovation Landscape Left to right: Sanjay Patel, Global Head of DD&T Innovation Capability Solutions & Services, Takeda; Gabriele Ricci, Chief Data and Technology Officer at Takeda; Tilak Banerjee, Head of Takeda ICC India inaugurating Takeda ICC India (Bengaluru) Takeda (TSE:4502/NYSE:TAK), a global leader in biopharmaceutical innovation, today announced the official opening of its Innovation Capability Center (ICC) in Bengaluru, India, a center where digital solutions will be built as part of Takeda's global digital transformation, which includes insourcing capabilities. This marks Takeda's first ICC in Asia, following successful establishments in Slovakia and Mexico. The ICC help support the company's dedication to advancing healthcare through innovative solutions. These cutting-edge solutions will help advance our operations and have an impact on Takeda's workforce, the patients that we serve and the planet for years to come. The launch of ICC India represents Takeda's strategic commitment to apply data and new digital technologies, such as artificial intelligence, having the potential to accelerate research and development with the ultimate goal of transforming the lives of patients. Takeda is focused on creating better health for people and a brighter future for the world, with a steadfast commitment to its core values: Integrity, Fairness, Honesty and Perseverance. With a rich history that dates back to 1781 in Osaka, Japan, Takeda has grown into a global biopharmaceutical leader, operating in approximately 80 countries, including in India for more than 13 years. The company's mission in India focuses on ensuring sustainable access to health care, bolstered by strategic partnerships. Takeda's diverse therapeutic portfolio addresses gastrointestinal disorders, rare diseases, immunology, oncology and vaccines, underscoring its commitment to data-driven innovation and transforming treatments. The establishment of this capability center underlines Takeda's ambition to transform into one of the most trusted, values-based, R&D-driven biopharmaceutical companies, tapping into Karnataka's vibrant ecosystem of innovation to serve patient needs. "The launch of our Bengaluru ICC is a pivotal moment for Takeda's digital transformation journey," said Gabriele Ricci, Chief Data and Technology Officer at Takeda. "Tapping into local talent is vital in our quest to create better health for people and a brighter future for the communities we serve. Investing in India's remarkable talent and technological expertise underscores Takeda's commitment leveraging local expertise to deliver innovative, data-driven solutions and sustainable growth." The ICC in India will develop key technology capabilities to fuel innovation by embracing data and digital solutions using an agile, patient-centric and solution focused approach. The ICC will concentrate on pioneering advancements across domains including: Artificial Intelligence (AI) and GenAI to enhance efficiency and predictive analytics in healthcare Device Engineering and Application Virtualization to drive innovation in product development and patient-centric solutions Data Science and Visualization to enable data-driven decision-making for improved patient outcomes "India was a natural choice for Takeda's first ICC in Asia," said Tilak Banerjee, Head of Takeda ICC India. "This strategic commitment will generate new jobs and further the company's global mission of delivering life-transforming treatments to patients." -- About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries

Japanese pharma Takeda launches innovation centre, eyes to onboard AI-driven talent

Takeda opens its first Innovation Capability Centre in Bengaluru, targeting to hire 750 professionals in AI, data science, and cybersecurity. The facility aims to advance AI in drug discovery, clinical trials, and patient care. The company plans to launch its Dengue vaccine in India by 2026 and expand its focus on inflammation, oncology, and rare conditions.Japanese pharmaceutical company Takeda inaugurated its first Innovation Capability Centre (ICC) in Bengaluru, marking its debut in Asia. The ICC aims to employ 750 professionals, including software engineers, data scientists, and cybersecurity experts, with a strong focus on AI-driven talent, the company said on Wednesday. Speaking to ET on the sidelines of the inauguration, Takeda's Chief Data and Technology Officer, Gabriele Ricci, said the company chose Bengaluru for its robust talent pool in data, digital, and technology, as well as its unique ecosystem of academia, startups, and tech partners. The CTO said it views AI as a key enabler in drug discovery, clinical trials, manufacturing, and patient care. "We are living in amazing times with the intersection of science and technology. Emerging technologies like AI, generative AI, and robotics offer unique opportunities to create solutions that can impact healthcare systems worldwide," Ricci said. Ricci added that the Bengaluru facility will focus on developing products such as a plasma-derived therapies donor management system and a global platform for healthcare professional (HCP) data. "The Indian team will also develop scalable, multi-language tools and other digital products to enhance patient support and care experiences," he said. Over the next few years, Takeda plans to expand its focus on therapeutic areas such as inflammation, oncology, and rare conditions, with investments in plasma-derived therapies and vaccines, Ricci said during the ICC launch. The company is currently undergoing clinical trials and regulatory approvals to launch its Dengue vaccine- Qdenga, in Indian markets by 2026. Takeda plans to leverage local manufacturing under the 'Make in India' initiative to deliver the vaccine. The pharma company has been improving its high-value late stage pipeline with plans to file eight regulatory filings between 2025-2029 and make revenue of $10 billion to $20 billion, as per Takeda's official website.